Skip to content
Disclosery

Fulcrum Equity Management: MLPX position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Fulcrum Equity Management on MLPX, newest first. How the timeline and the estimate are built.

Fulcrum Equity Management held 0 MLPX shares at 2025-09-30 per its 13F-HR filed 2026-01-06.

the latest 13F is the newest step

  1. period ended2025-09-30
    13F 0 shares
    Change vs previous 13F -13,972 shares

    13F-HR 0001737888-26-000001 filed by Fulcrum Equity Management
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  2. period ended2025-06-30
    13F 13,972 shares
    Change vs previous 13F -1,682 shares

    0.9% of the 13F portfolio, value $875,491.

    13F-HR 0001737888-25-000006 filed by Fulcrum Equity Management
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-03-31
    13F 15,654 shares
    Change vs previous 13F -3,303 shares

    1.09% of the 13F portfolio, value $998,859.

    13F-HR 0001737888-25-000004 filed by Fulcrum Equity Management
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2024-12-31
    13F 18,957 shares
    Change vs previous 13F -2,480 shares

    1.14% of the 13F portfolio, value $1,148,031.

    13F-HR 0001737888-25-000001 filed by Fulcrum Equity Management
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2024-09-30
    13F/A 21,437 shares
    Change vs previous 13F not available

    0.99% of the 13F portfolio, value $1,166,816.

    13F-HR/A 0001737888-24-000007 filed by Fulcrum Equity Management
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).